Aprogen Medicines Inc. / Fundamentals
Income statement
- Net revenue
€76.75M - Cost of goods sold
€57.34M - Gross profit
€19.41M - SG&A expenses
€59.80M - R&D expenses
€12.29M - EBITDA
-€45.77M - D&A
€5.00M - EBIT
-€58.78M - Interest expenses
€6.25M - EBT
-€83.08M - Tax expenses
-€1.29M - Net income
-€33.45M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
€29.46M - Changes in working capital
€21.73M - Operating cash flow
-€13.95M - Capex
€12.00M - Other investing cash flow
-€14.28M - Net investing cash flow
-€39.34M - Total cash dividends paid
€0.00 - Issuance of common stock
-€13.85K - Debt repayment
€78.04M - Other financing cash flow
€18.41M - Net financing cash flow
€96.43M - Foreign exchange effects
-€70.16K - Net change in cash
€41.59M - Cash at end of period
€80.75M - Free cash flow
-€1.95M
Balance sheet
- Cash and cash equivalents
€80.75M - Cash and short-term investments
€89.15M - Total receivables
€21.69M - Inventory
€38.42M - Other current assets
€2.55M - Total current assets
€151.80M - Property, plant & equipment
€224.95M - Goodwill
€27.70M - Intangible assets
€36.66M - Long-term investments
€0.00 - Other non-current assets
€46.16M - Total non-current assets
€335.46M - Total assets
€487.27M - Accounts payable
€4.20M - Short-term debt
€118.38M - Other current liabilities
€25.89M - Total current liabilities
€148.47M - Long-term debt
€19.81M - Deferred tax liabilities
€3.98M - Other non-current liabilities
€14.30M - Total non-current liabilities
€38.08M - Total liabilities
€186.56M - Common stock
€93.97M - Retained earnings
-€270.85M - Other equity
€0.00 - Total equity
€300.71M - Total liabilities and shareholders' equity
€487.27M
Company information
- Market capitalization
€117.19M - Employees
245 - Enterprise Value
€300.74B
Company ratios
- Gross margin
-
25.3% Even with peer group: 26.9% - EBITDA margin
-
-59.6% Much worse than peer group: 3.3% - EBIT margin
-
-76.6% Much worse than peer group: 0.4% - EBT margin
-
-108.3% Much worse than peer group: -1.3% - Net margin
-
-43.6% Much worse than peer group: -3.4% - ROE
-
-11.1% Worse than peer group: -0.1% - ROA
-
-6.9% Worse than peer group: 0.4% - Asset turnover
-
15.8% Much worse than peer group: 77.2% - FCF margin
-
-33.8% Much worse than peer group: -2.9% - FCF yield
-22.1% - Efficiency ratio
159.6% - Net sales per employee
-
€313.25K - Net income per employee
-
-€136.54K